- Bioventix
- 30 March 2026 13:19:49
Source: Sharecast
For the six months ended 31 December, revenue fell to £6.16m from £6.73m a year earlier, while pre-tax profit edged down to £4.85m from £5.05m.
On a constant currency basis, revenue was £6.4m and profit before tax £5.1m.
Closing cash balances increased to £5.3m from £5.1m, and the company maintained its interim dividend at 70p per share.
Bioventix said the main growth driver was its expanding portfolio of antibodies used in neurological disease testing, with royalties from Tau and other neuro antibodies rising five-fold to £150,000 from £30,000.
The revenue was currently related only to research-use-only assays for Alzheimer’s disease, with no in vitro diagnostic assays yet approved for routine clinical use.
Bioventix said its single monoclonal antibodies are now included in multiple assay designs under development by major diagnostics groups and specialist high-sensitivity platform providers targeting blood-based biomarkers for Alzheimer’s.
“The royalty dynamics above, together with our increasing footprint in our customer's Alzheimer's assay designs, are clear causes for optimism that our revenues will grow significantly into the future as IVD assays for routine clinical use are approved,” said chairman and chief executive Peter Harrison.
Sales of Bioventix’s vitamin D and other core antibodies were broadly in line with the prior year, reflecting the maturity of those products, while the company said challenging conditions in China had led to the loss of some limited revenue streams.
Troponin antibody sales were steady, although the company said it had yet to see a royalty uplift from Siemens’ revised troponin assay label approved by the FDA in late 2024.
Bioventix also said research continued on other neurological applications, including Tau tangle pathology, peripheral neuropathies and vascular dementia, while its water quality project using caffeine and paracetamol as markers of human-derived contamination in freshwater was progressing, with field trials of lateral flow devices expected in the second quarter of 2026.
The board said it remained confident in the outlook for the year ending 30 June 2026.
“In conclusion, the evolution of our business with a historic core of established SMAs being supplemented by a range of exciting new neuro SMAs is firmly taking shape,” Harrison said, adding that the company remained positive about opportunities in Alzheimer’s and other neurological diseases.
At 1300 BST, shares in Bioventix were up 10.91% at 1,525p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
